

News Release

March 18, 2026
Carna Biosciences, Inc.

Carna to Present Preclinical Findings on Monzosertib-Induced Cancer Cell Death at AACR Annual Meeting

Carna Biosciences, a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, announces that preclinical findings for monzosertib (AS-0141) will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22 in San Diego, California.

Monzosertib is a potent, selective, and orally bioavailable small molecule inhibitor of CDC7 (cell division cycle 7) kinase, currently in a Phase 1 clinical study in Japan in patients with solid and hematologic malignancies. The poster will highlight mechanistic insights into cell death induced by monzosertib in cancer cell lines.

Presentation Details

Publication Number: 2925

Poster title:	Monzosertib, a selective CDC7 inhibitor, induces cell death via premature mitosis promoted by the FOXM1-cyclinB1 axis
Session:	Experimental and Molecular Therapeutics
Session date:	Monday, 20 April, 2026
Presenter:	Hiroko Endo ¹ , Yu Nishioka ¹ , Mariko Hatakeyama ¹ , Youichi Tajima ² , Sayuri Ito ² , Akinori Arimura ¹ , Hisao Masai ² , Masaaki Sawa ¹

¹ Carna Biosciences, Inc., ²Tokyo Metropolitan Institute of Medical Science

The abstract is available at: <https://www.abstractsonline.com/pp8/#!/21436/presentation/3431>

About monzosertib (AS-0141)

CDC7 (cell division cycle 7) is a serine-threonine kinase that plays a critical role in DNA synthesis and is required for the activation of DNA replication origins throughout the S phase of the cell cycle. Inhibition of CDC7 in cancer causes lethal S phase or M phase progression, whereas normal cells survive, most likely through induction of cell cycle arrest at the DNA replication checkpoint. It has been reported in the literature that CDC7 is overexpressed in many types of cancers, therefore CDC7 is an attractive target for cancer drug development. Carna has successfully identified a selective and potent CDC7 inhibitor, monzosertib, with a unique mechanistic slow off-rate.

Contact:
Corporate Planning
Carna Biosciences, Inc.
TEL: +81-78-302-7075
<https://www.carnabio.com/english/>